Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Trellis Bioscience Raises $10 Million in Series B Venture Round

Abstract:
Trellis Bioscience, Inc., a privately held biotechnology company, announced today that it has raised $10 million in a Series B Preferred Stock venture capital financing. New investor Novartis Bioventures Ltd. led the round, with the participation of additional new investors Pac-Link Bio Venture Investment Corporation and Sagamore Bioventures LLC. Previous investors, Easton-Hunt Capital Partners, LP and Morgenthaler Partners VII LP also participated in the financing. Proceeds from the financing will be used to develop Trellis' own product candidates, as well as its corporate partnering product candidates, and for general corporate purposes.

Trellis Bioscience Raises $10 Million in Series B Venture Round

SOUTH SAN FRANCISCO, CA | Posted on February 13th, 2007

Trellis additionally announced that Markus Goebel, M.D., Ph.D., managing director of Novartis Bioventures, will join the Trellis Board of Directors.

"We are very pleased to have the participation of this high quality group of venture investors whose support further validates Trellis' technology and business strategy," said Brian C. Cunningham, Trellis' Chief Executive Officer. "This financing will help to transform Trellis from a technology platform company to a product-oriented biotechnology firm that generates its own therapeutic candidates in the areas of infectious disease and oncology. At the same time, we will continue to partner with other companies to commercially validate the advantages of Trellis CellSpot(TM) technology to rapidly identify important therapeutic antibodies as well as high-producing cell lines that can dramatically improve the productivity of antibody and other protein manufacturing processes."

####

About Trellis Bioscience
Trellis Bioscience, Inc. has developed a breakthrough technology platform for discovery and selection of very rare cells that produce ideal proteins such as antibodies, selected for specificity, selectivity, affinity, secretion rate and other desired characteristics. The company's proprietary CellSpot(TM) platform is at the convergence of nanotechnology, software, digital microscopy and biology and allows for a parallel evaluation of millions of cells simultaneously in a way that enables the valuable one in one million cells to be reliably identified and recovered. The technology has broad application in the discovery and production process development of therapeutic proteins. In addition to applying CellSpot(TM) to the discovery and manufacturing needs of partners, Trellis is developing a pipeline of native human antibodies for the treatment of infectious disease and oncology. More information about Trellis Bioscience can be found at http://www.trellisbio.com .

For more information, please click here

Contacts:
Trellis Bioscience, Inc.
Brian C. Cunningham, 650-616-1121

or
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

180 Degree Capital Corp. Leads Investment in TheStreet, Inc.; Investment Enables Removal of Capital Structure Overhang November 14th, 2017

Announcements

Thanks for the memory: NIST takes a deep look at memristors January 20th, 2018

New Method Uses DNA, Nanoparticles and Top-Down Lithography to Make Optically Active Structures: Technique could lead to new classes of materials that can bend light, such as for those used in cloaking devices January 18th, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project